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Quantifying the pharmacology  
of antimalarial drug combination 
therapy
Ian M. Hastings, Eva Maria Hodel & Katherine Kay†
Most current antimalarial drugs are combinations of an artemisinin plus a ‘partner’ drug from another 
class, and are known as artemisinin-based combination therapies (ACTs). They are the frontline drugs 
in treating human malaria infections. They also have a public-health role as an essential component of 
recent, comprehensive scale-ups of malaria interventions and containment efforts conceived as part of 
longer term malaria elimination efforts. Recent reports that resistance has arisen to artemisinins has 
caused considerable concern. We investigate the likely impact of artemisinin resistance by quantifying 
the contribution artemisinins make to the overall therapeutic capacity of ACTs. We achieve this 
using a simple, easily understood, algebraic approach and by more sophisticated pharmacokinetic/
pharmacodynamic analyses of drug action; the two approaches gave consistent results. Surprisingly, 
the artemisinin component typically makes a negligible contribution (≪0.0001%) to the therapeutic 
capacity of the most widely used ACTs and only starts to make a significant contribution to therapeutic 
outcome once resistance has started to evolve to the partner drugs. The main threat to antimalarial 
drug effectiveness and control comes from resistance evolving to the partner drugs. We therefore argue 
that public health policies be re-focussed to maximise the likely long-term effectiveness of the partner 
drugs.
Human malaria infections caused an estimated 214 million clinical cases and 438,000 deaths in 20151. The rel-
atively low case-fatality rate, even for the most virulent species, P. falciparum, is partly due to patient immu-
nity acquired after repeated infections, but is also attributable to the timely provision of effective malaria drugs. 
There is a constant threat of malaria evolving resistance to available drugs and recent observations that resist-
ance may have arisen to the most widely used antimalarial drug class, the artemisinins, has caused the World 
Health Organization to produce an emergency response in the Greater Mekong Sub-region to reduce its putative 
impact on the effectiveness of malaria treatment and control2. Artemisinin derivatives have to be deployed in 
combination with a ‘partner drug’ from a different drug class, the resulting drug combinations being known as 
artemisinin-based combination therapies (ACTs). One important operational question is to quantify the extent 
to which overall ACT cure rates may be threatened by resistance arising to their artemisinin components3. The 
impact of artemisinin resistance is generally assumed to be large (e.g. ref. 4 and 5) but there are few, if any, 
quantitative analyses to support this belief. Here we show that artemisinins make an extremely small contribu-
tion to overall ACT therapeutic capacity compared to their partner drugs, unless resistance has evolved to the 
partner drug, and argue that the debate over the impact and importance of artemisinin resistance needs to be 
re-interpreted in this light.
Results
An intuitive, ‘simple’ approach, and a more sophisticated pharmacokinetic/pharmacodynamic (PKPD) modelling 
approach, can be used to quantify the therapeutic capacity of antimalarial drugs. This is most easily quantified as 
the total Parasite Reduction Ratio (PRRtot), of partner drugs and artemisinins used in the current generation of 
ACTs (see Methods section). The therapeutic capacities are given in Table 1. Partner drugs have far more thera-
peutic capacity than the artemisinins (Table 1) so the latter make only an extremely small contribution, typically 
≪0.0001%, to overall therapeutic capacity of the ACT (Table 2). The PKPD method simulates 1,000 individual 
patients which allows the inter-patient variation in PRRtot to be incorporated (Fig. 1a). These results show that 
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the contribution of the artemisinins to total ACT therapeutic capacity is typically negligible when parasites are 
sensitive to the partner drug. The average contribution of artemisinins to ACTs based on the most widely used 
partner drugs (amodiaquine, lumefantrine, mefloquine, piperaquine) varies between 10−10.5 and 10−30 that of its 
partner drug using the simple method, and between 10−9 and 10−46 using the PKPD method. However, incor-
porating PK and PD variability suggests artemisinin may make a significant contribution in a small proportion 
of patients (Fig. 1b), although even if the artemisinin does make a significant contribution, the partner drug 
may still have sufficient therapeutic capacity to successfully eradicate the infection on its own. It is only when 
Drug PRRtot (simple method)
PRRtot (PKPD 
method)
Monotherapy cure rate 
(PKPD method)
Partner drugs (sensitive):
 AQ (103)15/2 = 1022.5 1.7 × 1020 86%
 LF (103)24.5/2 ≈ 1037 2.7 × 1035 90%
 MQ (103)28/2 = 1042 1.3 × 1056 94%
 PPQ (103)22/2 = 1033 3.2 × 1031 80%
 SP (102)46/2 = 1046 n/a n/a
Partner drugs (resistant):
 PPQR (103)8/2 = 1012 3.2 × 1013 55%
 SPR (102)9/2 = 109 n/a n/a
Artemisinins:
 ARq.d. 1012 4.8 × 1012 57.4%
 ARb.i.d 1020 1.2 × 1026 91.8%
 AS 1012 7.6 × 1010 43.2%
 DHA 1012 5.0 × 1010 35.3%
Table 1.  The therapeutic capacity of a range of antimalarial drugs, quantified by their PRRtot. The “simple” 
method uses Equation 1 for partner drugs, Equation 2 for artemisinins given once-daily over three days, and 
Equation 3 for artemether when given as six twice-daily doses. The PKPD method uses the approach outlined 
in Equation 4 and we include the partner drug monotherapy cure rates to quantify the degree of their drug 
sensitivity/resistance. The PRRtot for the PKPD method are the median values shown in Fig. 1a (note that we 
cannot currently undertake a PKPD analysis of SP for reasons given in the Supplementary Information File). 
The PKPD method assumes wide, but continuous, ranges of values for the key PK and PD parameters (see 
Supplementary Information File) which results in the distributions of PRRtot values on Fig. 1(a). This gives 
rise to an apparent discrepancy in this table i.e. that AQ has a lower therapeutic capacity (PRRtot) than PPQ 
but higher monotherapy cure rate. The reason is that PRRtot given in the table is the median of the distribution 
simulated (Fig. 1(a)) whereas cure rates depend on the proportion of patients with low PRRtot. Patients 
given AQ in our parametrisation have relatively tightly clustered PRRtot values which means the proportion 
of patients with a low PRRtot is small (see 5th centile values on Fig. 1(a)) so its failure rate is lower than for 
PPQ. Abbreviations: AQ = amodiaquine, AR = artemether, AS = artesunate, DHA = dihydroartemisinin, 
LF = lumefantrine, MQ = mefloquine, n/a = not applicable, PKPD = pharmacokinetic-pharmacodynamic 
modelling, PPQ = piperaquine, SP = sulfadoxine-pyrimethamine;. Subscripts: b.i.d = twice daily dosing, 
R = resistance, q.d. = once daily dosing.
ACT Simple method PKPD method
No resistance to partner drugs: 
 AQ + AS 1 × 10−10.5 2.1 × 10−9
 LF + ARb.i.d 4 × 10−17 3.5 × 10−10
 MQ + AS 1 × 10−30 5.4 × 10−46
 PPQ + DHA 1 × 10−21 5.1 × 10−22
 SP + AS 1 × 10−34 n/a
Parasites resistant to partner drugs:
 PPQR + DHA 1 × 100 9.9 × 10−5
 SPR + AS 1 × 103 n/a
Table 2. The contribution of artemisinins to total ACT therapeutic capacity. This is quantified as 
the ratio of the artemisinin PRRtot to partner drug PRRtot using the values in Table 1. The contribution 
for the PKPD method are the median values shown in Fig. 1b. Abbreviations: ACT = artemisinin 
combination therapy, AQ = amodiaquine, AR = artemether, AS = artesunate, auDKC = area under the 
drug kill curve, DHA = dihydroartemisinin, LF = lumefantrine, MQ = mefloquine, n/a = not applicable, 
PKPD = pharmacokinetic-pharmacodynamic modelling, PPQ = piperaquine, SP = sulfadoxine-
pyrimethamine; Subscripts: b.i.d = twice daily dosing, R = resistance. 
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resistance has arisen to the partner drugs that artemisinins start to make a contribution to its ACT therapeutic 
capacity (Table 2). In summary, artemisinins make a negligible contribution to overall ACT therapeutic capac-
ity when partner drugs are effective and only start to provide some protection once resistance starts to make 
the partner drug ineffective. Artemisinins play a role at this point (approximately halving failure rates6) but the 
long half-lives of partner drugs will further drive resistance eventually leaving artemisinins present as ineffective 
monotherapies7–10.
Discussion
It is important to recognise the distinction between therapeutic capacity (the potential parasite killing) of a drug, 
and its actual killing capacity. In an idealised situation, where there is no resistance and both drugs are effective, 
it is clear that artemisinins contribute most to the short-term clearance of an infection. As a simple example, 
assume an infection has 1011 parasites, each artemisinin dose has a parasite reduction ratio over 48 hours (PRR48) 
of 104, the partner drug has a PRR48 of 103, then by 48 hours the artemisinin will have killed 108 parasites and the 
partner drug 103, so artemisinin will have killed > 99.99% of the initial parasitaemia. It could be argued that this 
artemisinin killing is superfluous because the partner drug would have killed those parasites if the artemisinin 
had not been present, or was ineffective. However, it explains the basic principle that artemisinins are responsible 
for rapid initial parasite clearance, the high combined PRR48 observed after ACT treatment, and rapid alleviation 
Figure 1. Boxplots of drugs’ therapeutic capacity quantified as PRRtot. (a) Individual drugs used in ACTs. 
(b) The contribution of artemisinin to overall ACT therapeutic capacity in a variety of ACTs; this is measured 
as the ratio artemisinin PRRtot: partner drug PRRtot. Note that in all plots the upper “whisker” of the boxplot 
lies immediately above the box and is difficult to distinguish. We identify the 5th and 95th centiles of the data 
by horizontal red lines. [The box delimits the second and third quartiles of the data (i.e. the inter-quartile 
range, IQR) with the horizontal line in that box representing the median value; the whiskers are the upper/
lower quartile values plus/minus 1.5 times the IQR. Data points that lie outside the whiskers are regarded as 
outliers and are plotted individually. Note that the upper whiskers all lie virtually on top of the interquartile 
box due to the logarithmic scaling of the Y-axis]. Abbreviations: ACT = artemisinin combination therapy, 
AQ = amodiaquine, AR = artemether, AS = artesunate, DHA = dihydroartemisinin, LF = lumefantrine, 
MQ = mefloquine, PPQ = piperaquine, SP = sulfadoxine-pyrimethamine; Subscripts: b.i.d = twice daily dosing, 
R = resistance, q.d. = once daily dosing.
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of symptoms, while the partner therapeutic capacity is responsible for guaranteeing the long-term therapeutic 
outcome. The problems arise when this idealised situation does not apply and resistance starts to spread to one or 
both components of the ACT; this is the situation considered in this manuscript. Artemisinins in ACTs are largely 
protected by the partner drug providing there is no resistance to the latter: artemisinins have a short half-life so 
are always present with their partner drug (providing artemisinin monotherapy is not present) and the therapeu-
tic capacity of the partner drug means there will be negligible selection for artemisinin resistance through ACT 
use (because parasites resistant to artemisinin would be killed by the partner drug and would have no selective 
advantage). Conversely, the partner drug has a long half-life so persists as a monotherapy in patients after the 
artemisinin has been eliminated; this long period of persistence throws substantial selection pressure on resist-
ance to the partner drugs (see e.g. Fig. 1 of ref. 11). These dynamics means that ACT resistance is likely to arise 
in two distinct phases. Phase 1 is characterised by resistance eroding the therapeutic capacity of the partner drug 
to the point that its PRRtot approaches that of the artesunate (Table 1, Fig. 1) and clinical failures start to occur 
to the ACT. This is supported by field evidence from South East Asia where a recent review3 noted that “a high 
ACT failure rate has only been observed where resistance to the partner drug is present, regardless of whether 
artemisinin resistance is present”. Phase 2 then starts because both the artemisinin and partner drugs have similar 
therapeutic capacities so both contribute to cure and hence selection pressure exists for resistance to each drug. 
The dynamics after this point are impossible to predict: the effectiveness of selection for resistance for each drug 
depends on the frequency of resistance mutations and the magnitude of their effect. Again, field data illustrates 
Phase 2 with both MQ- and PPQ-based ACTs showing failures attributable to both partner drug and artemisinin 
resistance12,13. An important practical consequence of these dynamics is that artemisinin ‘resistance’ will not 
encode cross-resistance to all ACTs. The therapeutic capacity, and outcome, is largely determined by the partner 
drug and it is only once the early stages of resistance have started to degrade the partners’ therapeutic capacity 
that any pre-existing resistance to the artemisinins may accelerate the final stages of overall ACT resistance.
The term “ACT” is often used as a synonym for “effective drug” and it is often not clear in any given context 
what impact is due to the drug specifically having an artemisinin component, or what impact followed simply 
because the ACT was an effective drug combination. For example, Bhatt and colleagues14 estimated that ACT pro-
vision contributed 22% to recent declines in the incidence of falciparum malaria in Africa. It is not clear whether 
this contribution is due to the properties of the artemisinin component itself or is attributable to effective partner 
drugs. The results presented above suggest the latter: the artemisinins will have made little impact on therapeutic 
outcome (by which we mean the eventual cure/failure of treatment), and the short half-life of the artemisinins 
compared to partner drugs means the former will not have contributed to post-treatment prophylaxis of the 
drug. If artemisinins contribute little to overall ACT therapeutic capacity, and hence to therapeutic outcome, the 
obvious question is what do they contribute? One important property is their rapid action which alleviates symp-
toms, and may prevent patients progressing from uncomplicated to complicated or severe malaria during the first 
24 hours post-treatment. A second factor is that artemisinins kill immature gametocytes during the early stages of 
their ~10-day maturation period. Gametocytes have no clinical impact so this activity against immature gameto-
cytes has no clinical implications. However, it may have a public health benefit in reducing onward transmission 
of malaria. Recent modelling work investigating the impact of adding primaquine (which kills mature gameto-
cytes) to ACTs suggested its impact was negligible (e.g. ref. 15). If primaquine’s effect on killing mature, infectious 
gametocytes was negligible in terms of public-health, it seem logical to suppose that artemisinin’s ability to kill 
immature, non-infectious gametocytes will have a similarly small impact. This point is important because many 
of the commentaries on the threat posed by artemisinin resistance stress the public-health impact, for example 
that artemisinin resistance is “a major threat to further advances in malaria control”4, that it “threatens world-
wide initiatives to control and eliminate malaria”16, or that “the prospects for the elimination of malaria, are now 
threatened by the emergence of artemisinin resistance”17. We argue that it is important to place artemisinins 
within the context of ACT action. In particular, it is essential to distinguish their impact on rapidly reducing par-
asite load (at which they excel), from their ability to contribute to eventual therapeutic outcome, i.e. cure (which 
is often marginal; see Table 2 and Fig. 1). Based on our analyses, and more general properties of ACTs, there are, 
in our opinion, five major implications for resistance, existing or potential, to the current generation of ACTs.
First, the threat posed by resistance evolving to the partner drug. In an ACT where no resistance is present to 
either drug, the partner drug typically contributes > 99.9999% of the therapeutic capacity (Table 2, Fig. 1b) and 
is mainly responsible for ensuring the successful therapeutic outcome of treatment. Their long half-lives mean 
they persist as vulnerable monotherapies for significant periods of time after the short half-life artemisinin have 
been eliminated. These periods constitute a “window of selection” for resistance10,18 which is one of the three key 
drivers of resistance7. Their actions can be detected in the field (e.g. ref. 19 and 20) and can potentially shorten the 
useful therapeutic lifespan of ACTs (e.g. Box 2 of reference 8) irrespective of whether or not resistance is present 
to the artemisinin component.
Second, it is doubtful whether administering artemisinins once-daily is the optimal regimen given their very 
short half-lives. Twice-daily dosing appears to be a much more efficient use of artemisinins (see artemether in 
Table 1) and is discussed in more detail elsewhere21. This strategy of twice-daily dosing may therefore restore 
falling artemisinin effectiveness and also reduce the ability of artemisinin resistance to spread through parasite 
populations. In particular, the use of probably sub-optimal (i.e. once daily dosing) artemisinin regimens in efforts 
to eradicate putative artemisinin-resistant malaria populations (e.g. ref. 2) seems, at least to us, contra-indicated. 
This can be most conveniently achieved by simply splitting the ACT daily dosage into two halves, including the 
partner drug dosage to avoid having to provide artemisinin monotherapies.
Third equally, we share the widespread concerns about artemisinin resistance as detected by decreased para-
site clearance times (e.g. refs 4 and 5). Currently, this appears to be the main focus in the literature but it is clear 
that the concerns need to spread much wider than simply focussing on artemisinin “resistance”. Resistance may 
compromise the effectiveness of artemisinins in the monotherapy of severely ill patients, but there appears to be 
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less cause for alarm about in their role in ACTs. We do not share the cataclysmic predictions of its public-health 
impact claimed by some authors (see above) but we are likely to lose the extension of the therapeutic life-span that 
artemisinin can provide once partner drugs start to fail (Table 2B), which would allow time for policy changes to 
be implemented.
Third equally, it is possible that increased resistance to partner drugs and artemisinins is already present 
but has remained undetected through overreliance on parasite clearance rates as surveillance tools. Immunity is 
known to make a large contribution to parasite clearance rates22,23 and simulations suggest immunity completely 
dominates the clearance dynamics of parasites following artemisinin treatment unless drug effectiveness falls 
to very low levels (<~10% of original killing)24. The impact of human immunity in clearing erythrocytes con-
taining dead or dying parasites makes parasite clearance rates highly insensitive and non-specific diagnostics of 
resistance24–27. Consequently, parasite clearance rates represent poor surveillance tools and even large increases 
in drug resistance (to both the artemisinins and the partner drugs) may already be present in populations but 
remain undetected.
Fifth, the use of clearance rates as metrics of ACT resistance and effectiveness may miss substantial increases 
in ACT effectiveness that could be obtained by changes in deployment regimen. For example, Guinea Bissau 
overcame chloroquine resistance by the simple (but potentially toxic) strategy of doubling the dosage given28. 
Increasing dosage is one of the easiest ways to overcome resistance and it is highly likely that all antimalarial 
drugs were initially deployed at too low a dose; most have had their dosage increased29. The “problem” with ACTs 
is that failure rates are currently low (but see refs 11,12 and 30) so drug effectiveness cannot be directly assessed 
by clinical trials using cure/failure rates as the end follow-up. That leaves pharmacological modelling as the main 
(and possibly the only) way to quantify the impact of regimen changes for example, the proposed move towards 
triple-drug combination therapies for malaria31,32.
Modelling plays an increasingly important role in planning malaria control and interventions33 and requires a 
component that quantifies the impact of drugs on treatment outcome; for example Slater and colleagues34 recently 
modelled the public-health impact of artemisinin and partner drug resistance. Our recent pharmacological mod-
elling work on ACTs (op cit) has enabled us to contribute to this modelling agenda, and wider debates, by placing 
concerns about artemisinin resistance in a more objective, quantitative framework with ramifications for both 
treatment and public-health applications.
Methods
The simplest way to quantify the therapeutic capacity of antimalarial drugs is through their parasite reduction 
ratio (PRR)35,36, a strategy that dates back to Sir Ronald Ross37 who calculated a drug’s “single-dose reduction 
rate”. The PRR is defined as the ratio of the number of parasites at time of treatment divided by the number after 
a given amount of time has elapsed post-treatment. This time period is normally 48 hours as this is the time 
taken for P. falciparum parasites to pass through their asexual erythrocytic life cycle. We denote this metric as 
PRR48, so if a drug has a PRR48 of 103 it indicates that a proportion of 10−3 parasites survive one erythrocytic 
cycle in the presence of the drug. If a drug is present at active concentrations (i.e. killing at a maximum rate; see 
Supplementary Information File for further details) for c erythrocytic cycles post-treatment, then its therapeutic 
capacity can be quantified as the total PRR it has accumulated over those cycles, i.e.
= =PRR PRR PRR( ) ( ) (1)tot
c d
48 48
/2
Note that c is most conveniently obtained by estimating the number of days, d, post treatment that a drug is active, 
and dividing it by 2 to obtain the number of 48-hour erythrocyte cycles. So for example, if a drug is actively killing 
parasites for d = 20 days after treatment, it is killing for c = 20/2, i.e. ten 48-hour life cycles. A PRR48 of 103, typical 
of partner drugs35,36, would therefore generate a PRRtot = (103)10 = 1030, thus implying that only 10−30 parasites 
present at the start of treatment would survive the 20 days of active parasite killing. Given that malaria infections 
rarely exceed around 1012 parasites, any drug with a value of PRRtot > 1013 implies a fully effective drug but PRRtot 
serves as a key theoretical metric for the therapeutic capacity of the drug. As an example, lumefantrine has a 
PRRtot of ~1035 (Table 1). It will never be required to remove 1035 parasites from a single infection but this metric 
of therapeutic capacity gives an indication of how much ‘margin of error’ is associated with the drug therapy and 
hence how robust it is to variation in patients’ pharmacokinetics (e.g. Fig. 1a), their adherence to the regime, 
existing variation in parasites drug susceptibility, and to the first stages of drug resistance.
Artemisinins persist at active concentrations for much shorter periods of time, d, post-treatment but are gen-
erally ascribed a PRR48 = 104 (refs 35 and 36). It is not clear whether this PRR48 occurs after a single dose or after 
multiple doses but here we make the assumption (generous to artemisinins) that it occurs after a single dose. 
Three once-daily doses of an artemisinin, as occurs in most ACT regimens, will therefore generate
= = =PRR PRR( ) (10 ) 10 (2)tot 48
3 4 3 12
One exception to this ACT regimen of once-daily dosing over three days is the combination of artemether 
with lumefantrine which is given twice-daily over three days. When the recommended daily dose of artemether 
(~4 mg/kg) is given as one daily dose, artemether persists for around 6 hours post-treatment. When the same 
dose is halved (~2 mg/kg) and given twice daily, its duration of persistence post-treatment is reduced by one elim-
ination half-life (around 40 minutes to one hour) so the period of active parasite killing following each of the six 
doses is reduced to approximately 5 hours per dose. This gives PRRtot for twice daily artemether as
= 





=PRR (10 ) 10
(3)tot
4 56
6
20
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This increase in artemether therapeutic capacity (cf Equation 2) is caused solely by it being dosed twice-daily 
while maintaining the same daily total dose. It would apply to all artemisinins dosed twice-daily and is a remark-
able result that suggests that artemisinins regimens given once-daily are sub-optimal (discussed more fully 
elsewhere21).
This “simple” method to assess drug effectiveness requires knowledge only of clinical observations already 
widely cited and accepted in the literature (i.e. PRR48 and drug persistence post-treatment; see Supplementary 
Information File for details) and familiarity with the simple algebraic rule that (10x)y = 10xy used to produce 
Equation 1 and Equation 2. We also use a more nuanced PKPD approach to quantify a more sophisticated esti-
mate of the contribution of artemisinins to overall ACT drug killing. The PKPD methodology recognises that 
pharmacological parameters vary enormously between patients depending on how they absorb, metabolise, dis-
tribute and eliminate drugs (their pharmacokinetics, PK) and between malaria parasites depending on their drug 
sensitivity (their pharmacodynamics, PD) so artemisinins may play a more significant role in treatment of some 
patients, e.g. those who rapidly eliminate the partner drug and/or whose parasites are naturally less sensitive to 
the partner drug. The basis of the PKPD method is the following equation
∫= − −P P e e e (4)t
at f I t f D dt
0
( ) ( )
t
0
which may be easily understood intuitively: it states that the number of parasites, Pt, present at time t after treat-
ment depends on the initial number of parasites present at time of treatment, P0, augmented by growth, a, that 
has occurred during time t, offset against the amount of immune killing over time t, −f(I)t and also offset against 
the amount of drug killing over time t, i.e. f(D). Immunity is generally ignored38 so f(I) = 0. This is a fairly stand-
ard method for investigating the treatment of infectious diseases (for a review, see ref. 39). It was first applied to 
malaria by Hoshen et al.40 and Austin et al.41, further developed by Hoshen and colleagues42–45, sporadically used 
subsequently by other authors (e.g. refs 18,46 and 47) and more recently taken up by ourselves to develop the 
methodological extensions and calibrations required to model ACT treatment21,24,38,48–52. Equation 4 can be solved 
to find the predicted minimum number of parasites post-treatment, Pmin which allows PRRtot to be calculated as 
P0/Pmin.
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